Table 3.
Survivals: RFA combined with TACE versus RFA alone for HCC.
| Author/year |
n
(TACE+RFA/RFA) |
Tumor size (mean, cm) (TACE+RFA/RFA) |
Overall survival (%) (TACE+RFA/RFA) |
P |
|---|---|---|---|---|
| Kitamoto et al. [49]/2003 | 10/16 | 3.9/3.4 | ND | |
| Wang et al. [50]/2007 | 43/40 | ND | 68.3/57.6 (1-year) | <.05 |
| Shibata et al. [51]/2009 | 46/43 | ND | 84.8/84.5 (3-year) | .515 |
| Morimoto et al. [52]/2010 | 19/18 | 3.6/3.7 | 93/80 (3-year) | .369 |
| Peng et al. [47]/2010 | 120/120 | ND | 50/42 (5-year) | .045 |
HCC: hepatocellular carcinoma; ND: not described; RFA: radiofrequency ablation, TACE: trans catheter arterial chemoembolization.